O
12.31
-0.31 (-2.46%)
| Previous Close | 12.62 |
| Open | 12.64 |
| Volume | 1,946,719 |
| Avg. Volume (3M) | 2,360,556 |
| Market Cap | 2,141,878,656 |
| Price / Sales | 37.53 |
| Price / Book | 7.14 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 |
| Operating Margin (TTM) | -597.47% |
| Diluted EPS (TTM) | -1.11 |
| Quarterly Revenue Growth (YOY) | -27.60% |
| Total Debt/Equity (MRQ) | 28.66% |
| Current Ratio (MRQ) | 10.22 |
| Operating Cash Flow (TTM) | -145.46 M |
| Levered Free Cash Flow (TTM) | -87.96 M |
| Return on Assets (TTM) | -27.21% |
| Return on Equity (TTM) | -57.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Ocular Therapeutix, Inc. | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 1.38 |
|
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 3.82% |
| % Held by Institutions | 87.01% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Summer Road Llc | 30 Jun 2025 | 13,887,468 |
| Deltec Asset Management Llc | 30 Jun 2025 | 2,794,892 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (Scotiabank, 62.47%) | Buy |
| Median | 15.00 (21.85%) | |
| Low | 15.00 (HC Wainwright & Co., 21.85%) | Buy |
| 15.00 (Needham, 21.85%) | Buy | |
| Average | 16.67 (35.42%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 10.88 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 06 Aug 2025 | 20.00 (62.47%) | Buy | 12.50 |
| Needham | 05 Aug 2025 | 15.00 (21.85%) | Buy | 12.00 |
| HC Wainwright & Co. | 29 May 2025 | 15.00 (21.85%) | Buy | 8.14 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Aug 2025 | Announcement | Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR |
| 05 Aug 2025 | Announcement | Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights |
| 29 Jul 2025 | Announcement | Ocular Therapeutix™ to Report Second Quarter 2025 Financial Results on August 5, 2025 |
| 22 Jul 2025 | Announcement | Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences |
| 26 Jun 2025 | Announcement | Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company |
| 16 Jun 2025 | Announcement | Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025 |
| 28 May 2025 | Announcement | Ocular Therapeutix™ To Close Enrollment This Week for SOL-R, its Second Registrational Trial Evaluating AXPAXLI™ in Wet Age-Related Macular Degeneration |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |